[The modulation of hemostatic reactions in vitro and in vivo by representatives of regulatory peptide families].
Ashmarin. I P IP; Liapina. L A LA; Pastorova. V E VE
Key Findings
- Regulatory peptides can be grouped as neutral, clot‑promoting, or clot‑inhibiting based on their effects on hemostasis.
- Semax shows fibrinolytic (clot‑breaking) and antithrombotic activity in vivo.
- Combining Semax with heparin enhances anticoagulant effects compared to heparin alone.
Practical Outcomes
- For biohackers focused on cardiovascular health, Semax may be a candidate for supporting clot‑breakdown, especially if you already use anticoagulants like heparin. However, the evidence is from animal studies, so dosing and safety in humans are not established. Consider waiting for clinical trials before adding Semax to a personal protocol.
Summary
The paper reviews how different regulatory peptides affect blood clotting and breakdown. It finds that Semax, a peptide similar to ACTH, can help dissolve clots and act against thrombosis in animal tests, especially when paired with heparin. The authors suggest testing Semax alone or with heparin in people with clotting problems.
Abstract
Data available in the literature and the author's own findings of the effects of regulatory peptide (RP) and their analogues are summarized. MIF, TRH, and its analog PR-546, the paraopioid RP, leuenkephalin, dalargin, the ACTH analogue Semax, tafcin, thymosine, interleukin-1, vasopressin, oxytocin, bradykinin, defencin, and some proline-containing oligopeptides, such as Pro-Gly, Gly-Pro, Trp-Pro, Pro-Gly-Pro, Gly-Pro-Gly-Gly were studied. A complex of in vitro and in vivo tests identified three groups of RP: 1) neutral ones as to the hemostatic reactions studied; 2) stimulants of hypercoagulation and fibrin polymerization; 3) inhibitors of blood coagulation, increased fibrinolysis, and fibrin demopolymerization. The fibrinolytic and antithrombotic effects of Semax (in vivo), the procoagulative action of defencin, and the enhanced anticoagulant effects in the combinations of Semax-heparin and tafcin (in vivo) attract particular attention. Semax alone and in combination with heparin is recommended for clinical studies in respective hemostatic abnormalities.
Study Information
pubmed
1996